文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

奈玛特韦治疗与COVID-19后状况风险的关联

Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition.
PubMed 文献 · JAMA Intern Med · 2023-01-01
一句话结论在至少有1项重症危险因素的SARS-CoV-2感染者中,阳性检测后5天内口服奈玛特韦与180天COVID-19后状况风险降低相关(RR 0.74)。

该队列研究利用美国退伍军人事务部(VA)医疗数据库,纳入2022年1月3日至2022年12月31日期间SARS-CoV-2检测阳性、检测当日未住院、至少有1项进展为重症COVID-19危险因素且诊断后存活30天的患者。将阳性检测后5天内口服奈玛特韦者(n=35 717)与急性期未接受任何COVID-19抗病毒或抗体治疗者(对照组,n=246 076)比较,采用逆概率加权生存模型估计180天时的相对风险和绝对风险降低。结果显示,奈玛特韦与COVID-19后状况风险降低相关(RR 0.74;95%CI 0.72-0.77;ARR 4.51%;95%CI 4.01-4.99),并降低急性期后死亡(HR 0.53;95%CI 0.46-0.61;ARR 0.65%;95%CI 0.54-0.77)和急性期后住院(HR 0.76;95%CI 0.73-0.80;ARR 1.72%;95%CI 1.42-2.01)风险。作者认为,急性期奈玛特韦治疗可能降低急性期后不良健康结局风险。

要点

  • 在至少有1项重症危险因素的SARS-CoV-2感染者中,阳性检测后5天内口服奈玛特韦与180天COVID-19后状况风险降低相关(RR 0.74;95%CI 0.72-0.77;ARR 4.51%;95%CI 4.01-4.99)。
  • 奈玛特韦与急性期后死亡风险降低相关(HR 0.53;95%CI 0.46-0.61;ARR 0.65%;95%CI 0.54-0.77)。
  • 奈玛特韦与急性期后住院风险降低相关(HR 0.76;95%CI 0.73-0.80;ARR 1.72%;95%CI 1.42-2.01)。
  • 奈玛特韦与13项急性期后COVID-19后遗症(COVID-19后状况的组成部分)中10项风险降低相关,包括心血管系统(心律失常和缺血性心脏病)、凝血和血液系统疾病(肺栓塞和深静脉血栓)、疲劳和不适、急性肾脏病、肌肉疼痛、神经系统(神经认知障碍和自主神经功能障碍)以及气短。
  • 在未接种疫苗、接种疫苗和加强接种者中,以及在初次SARS-CoV-2感染和再感染者中,奈玛特韦均与COVID-19后状况风险降低相关。

适用人群与场景

  • 美国退伍军人事务部(VA)医疗数据库中2022年1月3日至2022年12月31日SARS-CoV-2检测阳性、检测当日未住院、至少有1项进展为重症COVID-19危险因素且诊断后存活30天的患者。
  • 纳入分析共281 793例,平均(SD)年龄61.99(14.96)岁,242 383例(86.01%)为男性。

处置流程与药物剂量

  • 奈玛特韦组:阳性SARS-CoV-2检测后5天内口服奈玛特韦(n=35 717)。
  • 对照组:急性SARS-CoV-2感染期间未接受任何COVID-19抗病毒或抗体治疗(n=246 076)。

研究设计与关键结果

  • 研究设计:队列研究,利用美国退伍军人事务部(VA)医疗数据库,比较阳性检测后5天内口服奈玛特韦者(n=35 717)与急性期未接受任何COVID-19抗病毒或抗体治疗者(对照组,n=246 076),采用逆概率加权生存模型估计180天结局。
  • 主要终点:奈玛特韦与COVID-19后状况风险降低相关(RR 0.74;95%CI 0.72-0.77;ARR 4.51%;95%CI 4.01-4.99)。
  • 13项急性期后COVID-19后遗症(COVID-19后状况的组成部分)中10项风险降低,包括心血管系统(心律失常和缺血性心脏病)、凝血和血液系统疾病(肺栓塞和深静脉血栓)、疲劳和不适、急性肾脏病、肌肉疼痛、神经系统(神经认知障碍和自主神经功能障碍)以及气短。
  • 急性期后死亡:奈玛特韦与风险降低相关(HR 0.53;95%CI 0.46-0.61;ARR 0.65%;95%CI 0.54-0.77)。
  • 急性期后住院:奈玛特韦与风险降低相关(HR 0.76;95%CI 0.73-0.80;ARR 1.72%;95%CI 1.42-2.01)。
  • 亚组:在未接种疫苗、接种疫苗和加强接种者中,以及在初次SARS-CoV-2感染和再感染者中,奈玛特韦均与COVID-19后状况风险降低相关。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 作者结论:在至少有1项重症危险因素的SARS-CoV-2感染者中,阳性检测后5天内奈玛特韦治疗与COVID-19后状况风险降低相关,且不受疫苗接种状态和既往感染史影响;总体研究结果提示,急性期奈玛特韦治疗可能降低急性期后不良健康结局风险。

对床旁实践的改变

  • 对于至少有1项进展为重症COVID-19危险因素的SARS-CoV-2感染者,在阳性检测后5天内口服奈玛特韦与180天COVID-19后状况、急性期后死亡和急性期后住院风险降低相关。
  • 作者认为,急性期奈玛特韦治疗可能降低急性期后不良健康结局风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Post-COVID-19 condition (PCC), also known as long COVID, affects many individuals. Prevention of PCC is an urgent public health priority.

OBJECTIVE: To examine whether treatment with nirmatrelvir in the acute phase of COVID-19 is associated with reduced risk of PCC.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study used the health care databases of the US Department of Veterans Affairs (VA) to identify patients who had a SARS-CoV-2 positive test result between January 3, 2022, and December 31, 2022, who were not hospitalized on the day of the positive test result, who had at least 1 risk factor for progression to severe COVID-19 illness, and who had survived the first 30 days after SARS-CoV-2 diagnosis. Those who were treated with oral nirmatrelvir within 5 days after the positive test (n = 35 717) and those who received no COVID-19 antiviral or antibody treatment during the acute phase of SARS-CoV-2 infection (control group, n = 246 076) were identified.

EXPOSURES: Treatment with nirmatrelvir or receipt of no COVID-19 antiviral or antibody treatment based on prescription records.

MAIN OUTCOMES AND MEASURES: Inverse probability weighted survival models were used to estimate the association of nirmatrelvir (vs control) with post-acute death, post-acute hospitalization, and a prespecified panel of 13 post-acute COVID-19 sequelae (components of PCC) and reported in relative scale as relative risk (RR) or hazard ratio (HR) and in absolute scale as absolute risk reduction in percentage at 180 days (ARR).

RESULTS: A total of 281 793 patients (mean [SD] age, 61.99 [14.96]; 242 383 [86.01%] male) who had a positive SARS-CoV-2 test result and had at least 1 risk factor for progression to severe COVID-19 illness were studied. Among them, 246 076 received no COVID-19 antiviral or antibody treatment during the acute phase of SARS-CoV-2 infection, and 35 717 received oral nirmatrelvir within 5 days after the positive SARS-CoV-2 test result. Compared with the control group, nirmatrelvir was associated with reduced risk of PCC (RR, 0.74; 95% CI, 0.72-0.77; ARR, 4.51%; 95% CI, 4.01-4.99), including reduced risk of 10 of 13 post-acute sequelae (components of PCC) in the cardiovascular system (dysrhythmia and ischemic heart disease), coagulation and hematologic disorders (pulmonary embolism and deep vein thrombosis), fatigue and malaise, acute kidney disease, muscle pain, neurologic system (neurocognitive impairment and dysautonomia), and shortness of breath. Nirmatrelvir was also associated with reduced risk of post-acute death (HR, 0.53; 95% CI, 0.46-0.61); ARR, 0.65%; 95% CI, 0.54-0.77), and post-acute hospitalization (HR, 0.76; 95% CI, 0.73-0.80; ARR, 1.72%; 95% CI, 1.42-2.01). Nirmatrelvir was associated with reduced risk of PCC in people who were unvaccinated, vaccinated, and boosted, and in people with primary SARS-CoV-2 infection and reinfection.

CONCLUSIONS AND RELEVANCE: This cohort study found that in people with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe disease, treatment with nirmatrelvir within 5 days of a positive SARS-CoV-2 test result was associated with reduced risk of PCC across the risk spectrum in this cohort and regardless of vaccination status and history of prior infection; the totality of findings suggests that treatment with nirmatrelvir during the acute phase of COVID-19 may reduce the risk of post-acute adverse health outcomes.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Xie Y, Choi T, Al-Aly Z, et al. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. JAMA Intern Med. 2023. PMID: 36951829. doi:10.1001/jamainternmed.2023.0743

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。